Reneuron Share Discussion Threads

[masingi] 02/10/2019 11:17

Martinfrench

There has been no fall in vision acuity improvement in any patient. The effect you noticed is due to patients enrolled into the later trial that are not counted in months 6 and 9 as they have not been on the trial long enough.

Data used for months one to three includes six patients.

Data used for month six includes three patients.

Data used for month nine is just one patient.

Therefore, the visual acuity improvement of the single patient that has been in the trial for 9 months is shown in it's singular perfection only in the 9 month data, the contribution it makes to the average figures in previous months is overshadowed by the even greater improvements from the more recent recruits that are included in those averages.

Hope this makes sense! :)

I suspect a number of investors may have misinterpreted the data. It takes more than a cursory examination to understand what it means.

[martinfrench] 02/10/2019 11:11

and the "drop" between months 6 to 9 needs to be explained, if it actually is a drop....that would reduce the effictiveness of the treatment and i seriously hope it doesnt invalidate the model as stem cells are supposed to one off treatments, not ongoing.

again, should be explained but isnt, and again, terrible RNS.

[s1zematters] 02/10/2019 11:09

The rocket school are on the phone Martin, they reckon you cheated your rocket science exam?


martinfrench - 01 Oct 2019 - 15:36:42 - 7099 of 7153 ReNeuron - a leading, clinical-stage stem cell business - RENE
Think people just know how Rene's price history has worked, based on results and expect the same.

Add to that very illiquid and trades mean something and you get price rises.

Not rocket science

[jammydodger1] 02/10/2019 11:07

So good that the share price has gone dowweeeeeeeeee

[s1zematters] 02/10/2019 11:06

gapdown to 190 looks like a death star tractor beam here ... aimho.

Really Mr cheese eating monkey, it wasn't me who mention brexit first?

[martinfrench] 02/10/2019 11:05

think you have the wrong board sizematters

one thing which i dont think anyone has picked up on but i will here, is the mean change in the untreated eye.....which seems to increase along with the treated eye, then drops 1 letter on average from months 6 to 9.

Is this due to the treated eye putting less strain on the untreated eye and therefore there is a secondeary benefit ?

that is a guess but should i really have to be guessing what really might be going on ?

[s1zematters] 02/10/2019 10:57

Thank you for the heads up Bantam175, being a noob i thought the FTSE was following the Dow 343 fall yesterday and the Dow futures being down 170 today on U.S. manufacturing posted the weakest reading since the end of the last recession.
Silly me for not realising the falls in Asia and the US and Europe was all Brexit related!

Still using your logic you must agree that the markets see Brexit as a success as the ftse was circa 6200 on the day before the EU vote and now it's higher!

Let me guess; only the falls are Brexit related and when the ftse goes up it's world economics, right??

[rrb] 02/10/2019 10:49

this will recover. results are positive and we will see more upside into second week of october. Today's little bit of profit taking not ideal but these are massively underpriced at these levels.

[king1pin2] 02/10/2019 10:38

Perhaps its true to say that most savvy investors dont pay to much attention to the fine detail and dont get to close to a share.
I think it was a badly worded rns and thats the reason we fell back today but lets hope normal service resumes at this lower level.

[masingi] 02/10/2019 10:31

I suspect some people misinterpreted the results. It takes more than a cursory inspection to figure them out. At first sight it does look like an apparent drop-off in effect at 9 months, which is false.

[bantam175] 02/10/2019 10:31

No deal Brexit fears driving everything down today. Markets being mangled. Ideal chance to get in/top up imo.

[eggy6198] 02/10/2019 10:24

No that isnt true. This drop is a lack of understanding of what they are invested in. However any companies on side lines will now have increased intrest.

This drop isnt rational but such is life and the market

[small crow] 02/10/2019 10:21

I doubt the problem is the failure rate of the surgical procedure - every surgical procedure has failures, especially in the developmental stage. Instead, I wonder whether some investors were expecting, in addition, a commercial announcement? Was that what some had been led to believe?

[wigwammer] 02/10/2019 10:07

Agree the point is of interest. But the company state it is not product related, and a key purpose of early stage trials is to learn and improve procedure.. "no patients experiencing product-related serious adverse events and two patients experiencing surgical procedure-related loss of vision.

[martinfrench] 02/10/2019 09:53

Wholly agree it's the surgical procedure issues driving this down.

Def need more detail, although isn't laser eye surgery 95 percent successful ?

Correct me if wrong

[dickbush] 02/10/2019 09:48

There is definitely an element of buy the rumour sell the news, but I would also like to know what went wrong in the surgical procedure for two patients. Presumably, this will be the first question after Pravin Dugel has made his presentation unless he goes into detail. Given a good explanation, the middle column figures look very good to me. Presumably, we'll get an update in 3 months time.

[chrisis33] 02/10/2019 09:41

The issue is 2 patients lost their sight and there's insufficient detail in the RNS about this.

[wigwammer] 02/10/2019 09:32

The results are highly encouraging, and the only reason people are disappointed is because the early data with more impaired patients achieved unprecedented numbers. Look at today's report and compare the efficacy with blockbuster peer results. "Although still early days in terms of duration of response and with small patient numbers, this compares favourably with +6 to +11 average letter gains (after 12 months) observed with blockbuster ophthalmology drugs (e.g. Lucentis or Eylea), while gene therapy approaches in RP have yet to demonstrate a meaningful, if any, improvement in visual acuity."

[king1pin2] 02/10/2019 09:30

To be honest Perhaps its another oppertunity to pick up some more at the £2 mark .
I kicked myself for missing the last buying oppertunity below £2 so it could end up doing me a favor.

[martinfrench] 02/10/2019 09:23

And I'm bloody sure they would have given more detail on the surgical procedure issues in more normal times.

It's just bit amateur this particular rns

[martinfrench] 02/10/2019 09:19

The RNs to me looks like it was rushed out, could Def have been better put together and a lot clearer.

Looks like hot money exiting for now,
What we do need is deals, that is what validates the technology

[rayrac] 02/10/2019 09:19

Trouble is, two apparently lost what remained of their sight? Not caused by renes product, but by the procedure?

[king1pin2] 02/10/2019 09:11

Without doubt Eggy6198 but anything thats negitive will be picked up and sold into .

[hashertu] 02/10/2019 09:11

I thought the results were very encouraging.
So does my friend, whose son has the condition.
We will probably get to see individual patient progress, month by month, in the papers presented on 10/12 October.

[marwalker] 02/10/2019 09:08

Thanks Masingi and masw for the comments re. 6 and 9 month results.

I think you both must be correct but, I do think there could be a better way to explain results. Especially when below the table is a comment that after the strong results from the first 3 patients other results were not so good.